+

WO1998010795B1 - Tumor homing molecules, conjugates derived therefrom, and methods of using same - Google Patents

Tumor homing molecules, conjugates derived therefrom, and methods of using same

Info

Publication number
WO1998010795B1
WO1998010795B1 PCT/US1997/016086 US9716086W WO9810795B1 WO 1998010795 B1 WO1998010795 B1 WO 1998010795B1 US 9716086 W US9716086 W US 9716086W WO 9810795 B1 WO9810795 B1 WO 9810795B1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
page
new
molecule
seq
Prior art date
Application number
PCT/US1997/016086
Other languages
French (fr)
Other versions
WO1998010795A3 (en
WO1998010795A2 (en
WO1998010795A9 (en
Filing date
Publication date
Application filed filed Critical
Priority to AU44122/97A priority Critical patent/AU4412297A/en
Priority to CA002265484A priority patent/CA2265484C/en
Priority to EP97942422A priority patent/EP0927045B1/en
Priority to JP10513856A priority patent/JP2001501600A/en
Priority to DE69734887T priority patent/DE69734887T2/en
Publication of WO1998010795A2 publication Critical patent/WO1998010795A2/en
Publication of WO1998010795A3 publication Critical patent/WO1998010795A3/en
Publication of WO1998010795B1 publication Critical patent/WO1998010795B1/en
Publication of WO1998010795A9 publication Critical patent/WO1998010795A9/en

Links

Abstract

The present invention provides tumor homing molecules, which selectively home to a tumor. The invention also provides methods of using a tumor homing molecule to target an agent such as a drug to a selected tumor or to identify the target molecule expressed by the tumor. The invention also provides methods of targeting a tumor containing angiogenic vasculature by contacting the tumor with a molecule that specifically binds an αv-containing integrin. The invention further provides molecules that can selectively home to angiogenic vasculature. In addition, the invention provides a target molecule, which is specifically bound by a tumor homing molecule and is expressed by angiogenic vasculature. The invention also provides antibodies that bind to the target molecule and peptidomimetics that competitively inhibit binding of a ligand to the target molecule.

Claims

AMENDED CLAIMS
[received by the International Bureau on 15 May 1998 (15.05.98); original claim 35 amended; new claims 73-78 added; remaining claims unchanged (2 pages)]
35. A tumor homing peptide selected from the group consisting of CLSGSLSC (SEQ ID NO: 4) and CGSLVRC
(SEQ ID NO: 5) .
36. A tumor homing molecule identified by in vivo panning, comprising the steps of:
a) administering to a first subject having a tumor a library of diverse molecules;
b) collecting a sample of the tumor;
c) identifying a molecule that homes to said tumor;
d) collecting a sample of normal tissue corresponding to said tumor; and
e) determining that said molecule that homes to said tumor is not present in said normal tissue, thereby identifying said molecule as a tumor homing molecule,
provided said molecule is not an antibody.
37. A method of directing a moiety to a tumor, comprising contacting the tumor with the conjugate of claim 1.
38. The method of claim 37, wherein said contacting step is performed in vi tro .
39. The method of claim 37, wherein said contacting step is performed in vivo.
72. The method of claim 69, wherein said molecule is CDCRGDCFC (SEQ ID NO: 14) .
73. A tumor homing peptide selected from the group consisting of CNGRC (SEQ ID NO : 8) and
CNGRCVSGCAGRC (SEQ ID NO: 3) .
74. The conjugate of claim 1, wherein said moiety induces apoptosis in a cell.
75. A tumor homing peptide, comprising the amino acid sequence GSL.
76. A target molecule, which is expressed in tumor vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence GSL.
77. A target molecule, which is expressed in angiogenic vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence GSL.
78. A target molecule, which is expressed in angiogenic vasculature, wherein said target molecule binds a tumor homing peptide comprising the amino acid sequence NGR.
STATEMENT UNDER ARTICLE 19
Upon entry of the amendments, claims 1 to 78 will be pending. The amendments shown above and included on the Substitute pages are supported for the following reasons.
The specification has been amended at page 34, lines 9-10, to correctly indicate that the size of a phage is 900-1000 nm. Support for the amendment is provided, in part, by the language at page 34, as well as by knowledge in the art regarding the size of M13 bacteriophage, which harbor the fuse 5 vector (-see page 70, lines 11-13; and Exhibit A, Pasqualini et al . , Nature Biotechnol. 15:542 (1997), at page 545, right column second paragraph, indicating phage are 900 nm in length) . Thus, the amendment merely corrects an omission in not deleting a question posed prior to filing the specification and is supported, in part, by the specification and by knowledge in the art and, therefore, does not add new matter. Entry of Substitute page 34, containing the amended language, therefore, respectfully is requested.
Claim 35 has been amended to cancel recitation of the peptide of SEQ ID NO: 3, which has been added to new claim 73, and to insert therefor the peptide of SEQ ID NO: 4, which is supported in Table 2 (page 80, line 14) . The amendment is made to include only peptides sharing a "GSL" motif in claim 35 and, similarly, to include only peptides having a "CNGRC" motif in new claim 73. Thus, new claim 73 recites the peptide of SEQ ID NO: 3 and the peptide, CNGRC (SEQ ID NO: 8) . New claim 73, including the CNGRC peptide, is supported, for example, at page 38, line 35, to page 39, line 2, which indicates that CNGRC is a tumor homing peptide. Thus, the amendment to claim 35 and new claim 73 are supported by the specification and the claims as filed and do not add new matter.
New claim 74 also has been added. New claim 74 is supported, for example, at page 45, lines 14-19, and, therefore, does not add new matter. New claim 75 is supported, for example, at page 4, lines 13-19; at page 38, lines 6-33; and at page 40, lines 27-35, which indicate that "GSL" containing peptides are considered within the claimed invention, and, therefore, the new claims do not add new matter .
New claims 76 to 78 are based, in part, on originally filed claim 52 and are supported, for example, at page 67, line 34, to page 68, line 17, and, for example, at page 4, lines 13-19, and page 5, lines 13-16. Thus, new claims 76 to 78 do not add new matter.
For the above reasons, it is submitted that the amendments to the claims and the new claims do not add new matter. Accordingly, entry of Substitute pages 95 and 100, containing the amended claim 35 and new claims 73 to 78, respectfully is requested.
Entry of Substitute pages--35, 95 and 100 respectfully is requested. The Examiner is invited to contact the undersigned attorney or Cathryn Campbell if there are any questions relating to the subject application.
PCT/US1997/016086 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using same WO1998010795A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU44122/97A AU4412297A (en) 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
CA002265484A CA2265484C (en) 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using same
EP97942422A EP0927045B1 (en) 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using same
JP10513856A JP2001501600A (en) 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using the same
DE69734887T DE69734887T2 (en) 1996-09-10 1997-09-10 TUMOR FINDING MOLECULES, DIVIDING CONJUGATES, AND METHOD FOR USE THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71006796A 1996-09-10 1996-09-10
US08/710,067 1996-09-10

Publications (4)

Publication Number Publication Date
WO1998010795A2 WO1998010795A2 (en) 1998-03-19
WO1998010795A3 WO1998010795A3 (en) 1998-05-22
WO1998010795B1 true WO1998010795B1 (en) 1998-07-16
WO1998010795A9 WO1998010795A9 (en) 2001-06-21

Family

ID=24852493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016086 WO1998010795A2 (en) 1996-09-10 1997-09-10 Tumor homing molecules, conjugates derived therefrom, and methods of using same

Country Status (6)

Country Link
EP (1) EP0927045B1 (en)
JP (1) JP2001501600A (en)
AU (1) AU4412297A (en)
CA (1) CA2265484C (en)
DE (1) DE69734887T2 (en)
WO (1) WO1998010795A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186810B2 (en) 1998-10-23 2007-03-06 Amgen Inc. Modified peptides as therapeutic agents
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516055A (en) * 1997-09-10 2001-09-25 ザ バーナム インスティチュート Methods for identifying molecules that home to the angiogenic vasculature in tumors
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
EP1062232B1 (en) 1998-03-13 2008-09-10 The Burnham Institute Molecules that home to various selected organs or tissues
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
DE19845798A1 (en) * 1998-09-29 2000-04-13 Schering Ag Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ES2388341T3 (en) 1998-10-23 2012-10-11 Kirin-Amgen Inc. Dimeric thrombopoietin mimetic peptides that bind to the MPL receptor and that have thrombopoietic activity
CA2359633A1 (en) * 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US7049140B1 (en) 1999-04-29 2006-05-23 Vanderbilt University X-ray guided drug delivery
WO2001009611A2 (en) * 1999-07-29 2001-02-08 University Of Vermont And State Agricultural College An vivo identification of specific binding molecules for cancer detection
JP2003520808A (en) * 2000-01-21 2003-07-08 ザ バーナム インスティチュート Chimeric prostate homing peptide with pro-apoptotic activity
US7109303B2 (en) 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (en) 2000-02-15 2003-07-15 San Raffaele Centro Fond MODIFIED CYTOKINES FOR USE IN CANCER THERAPY.
JP2003526683A (en) 2000-03-15 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Peptidase-cleavable targeted antineoplastic drugs and their therapeutic use
DE60111733T2 (en) 2000-04-12 2006-05-18 Amersham Health As INTEGRIN BINDING PEPTIDE DERIVATIVES
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
US7666391B2 (en) 2001-06-01 2010-02-23 Burnham Institute For Medical Research Breast homing peptides and methods of identifying same using aminopeptidase P
IL159310A0 (en) 2001-07-10 2004-06-01 Amersham Health As Peptide-based compounds
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
DE60230822D1 (en) * 2001-11-08 2009-02-26 Burnham Inst PEPTIDES WITH HOMING FOR LYMPHOTIC TARTOR AND ITS USE
CA2467836A1 (en) 2001-11-20 2003-09-04 Duke University Interfacial biomaterials
CA2476556A1 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
EP1346729A1 (en) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Targeting of myocardial angiogenesis through CD13/APN
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2004015392A2 (en) * 2002-08-08 2004-02-19 Targeted Molecules Corporation Improved method to identify targeting molecules
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US7393653B2 (en) 2002-09-06 2008-07-01 The Burnham Institute Methods of modulating cell death based on the Bit1/AES regulatory pathway
MXPA05005469A (en) * 2002-11-25 2005-09-08 Attenuon Llc Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof.
US20050009740A1 (en) * 2003-03-31 2005-01-13 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US7122353B2 (en) 2003-08-05 2006-10-17 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
MX2007000216A (en) 2004-07-08 2007-03-15 Amgen Inc Therapeutic peptides.
CN101052408B (en) * 2004-09-07 2013-03-27 伯纳姆研究院 Peptides that selectively home to heart vasculature and related conjugates and methods
EP1831254B1 (en) 2004-12-23 2012-06-06 Molmed SpA Conjugation product
ITMI20050328A1 (en) 2005-03-03 2006-09-04 Univ Degli Studi Milano PEPTIDOMIMETRIC COMPOUNDS AND PREPARATION OF BIOLOGICALLY ACTIVE DERIVATIVES
NZ569818A (en) 2005-12-16 2012-07-27 Catherine M Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2008136869A2 (en) * 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
FI20075483A0 (en) * 2007-06-25 2007-06-25 Licentia Oy New peptide
MX2010009530A (en) * 2008-02-27 2010-11-30 Yeda Res & Dev Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors.
BRPI0920108A2 (en) * 2008-10-23 2016-12-13 Steba Biotech N V cyclic peptidomimetic containing argin, glycine, aspartic acid (rgd), cyclic peptidomimetic conjugate containing rgd, pharmaceutical composition, conjugate and use thereof.
CN102265158A (en) 2008-12-23 2011-11-30 通用电气健康护理有限公司 Application of 99mtc peptide-based compound as a bone marrow imaging agent
FR2968662B1 (en) 2010-12-10 2013-11-22 Roussy Inst Gustave NOVEL PRE-ACTIVE OXAZAPHOSPHORINE DERIVATIVES, USE AND METHOD OF PREPARATION
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
CA2919088A1 (en) * 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugates for delivery of rnai triggers to tumor cells in vivo
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
CN106518965A (en) * 2015-09-10 2017-03-22 华东理工大学 Polypeptide probe for specific identification of lysophosphatidic acid, preparation and applications thereof
WO2018148595A1 (en) 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
IL282748B1 (en) 2018-11-05 2025-03-01 Bayer Pharma AG Cytostatic conjugates with integrin ligands
WO2023057813A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
EP4412655A1 (en) 2021-10-04 2024-08-14 Vincerx Pharma GmbH Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder
CN118354796A (en) 2021-10-04 2024-07-16 文赛克斯制药有限责任公司 Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5845594A (en) * 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0987275B1 (en) * 1995-09-11 2008-01-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186810B2 (en) 1998-10-23 2007-03-06 Amgen Inc. Modified peptides as therapeutic agents
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Similar Documents

Publication Publication Date Title
WO1998010795B1 (en) Tumor homing molecules, conjugates derived therefrom, and methods of using same
DE69629127T2 (en) DISCONNECTING MEDIUM FOR IgG AND PROTEIN A VARIANT
JP7417432B2 (en) New linker, its production method and its application
CA2265484A1 (en) Tumor homing molecules, conjugates derived therefrom, and methods of using same
JP4229704B2 (en) Fc region polypeptide binding molecule
Fourie et al. Common and divergent peptide binding specificities of hsp70 molecular chaperones.
DE69526665T2 (en) ANTI-BINDING PEPTIDES (ABTIDES) FROM PEPTIDE LIBRARIES
CA2204535A1 (en) Molecules that home to a selected organ or tissue in vivo and methods of identifying same
JPS62500100A (en) Acid-cleavable compounds
WO2003046560B1 (en) Self-assembly molecules
CA2583009A1 (en) Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
DE69731626D1 (en) SH3-BINDING PEPTIDES OF CORTACTIN AND THEIR USE
JP2006521819A (en) Intracellular transport of small molecules, proteins, and nucleic acids
DE69938054D1 (en) ANTIBODY VARIANTS HAVING HIGHER BINDING SAFFINITIES COMPARED TO PARENTAL ANTIBODIES
White et al. Preparation of site-specific antibodies to acetylated histones
CA2305597A1 (en) Affinity markers for human serum albumin
Oblas et al. Analysis of receptor-ligand interactions using nitrocellulose gel transfer: application to Torpedo acetylcholine receptor and alpha-bungarotoxin
CA2193323C (en) Process for preparing a synthetic calibrator for use in sandwich immunoassays, which calibrator consists of an antibody against one of the antibodies used in the assay and of a sequence of the analyte
Benditt et al. Interaction of a nuclear location signal with isolated nuclear envelopes and identification of signal-binding proteins by photoaffinity labeling.
EP0650053B1 (en) Synthetic standard for immunoassays
Davis et al. Diversity in membrane binding sites of ankyrins: brain ankyrin, erythrocyte ankyrin, and processed erythrocyte ankyrin associate with distinct sites in kidney microsomes
ATE542138T1 (en) HER-2 BINDING ANTAGONISTS
Morrison et al. Determination of the structural domain of ApoAI recognized by high density lipoprotein receptors.
WO1990006323A3 (en) Chimeric proteins incorporating a metal binding protein
Yoshiya et al. Development of trityl group anchored solubilizing tags for peptide and protein synthesis
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载